NCT06056258已完成不适用
A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy of VL-NL-02 on Sleep and Mood.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 10
- 主要终点
- To assess the efficacy of Vl-NL-02 on sleep quality using the Insomnia Severity Index (ISI).
研究概览
简要总结
The goal of this clinical trial is to study the impact of VL-NL-02 in improving sleep quality, restorative sleep complaints, quality of life, stress levels, and sleep stages.
48 participants are expected to be randomized in a ratio of 1:1 to receive either VL-NL-02 or placebo and will be assigned a unique randomization code. Each group will have at least 20 completed participants after accounting for a dropout/withdrawal rate of 17%. The intervention duration for all the study participants is 21 days.
Participants will be asked to fill multiple questionnaires to assess sleep quality and mood imbalance.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
Double blind
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Individuals aged between ≥ 18 and ≤ 50 years with a moderately active lifestyle as assessed International Physical Activity Questionnaire - Short form (IPAQ - SF)
- •Individuals with mild to moderate sleeping issues as assessed by an ISI score of ≥ 8 and ≤ 21
- •Individuals with a history of at least 3 episodes of sleep disturbances in the last month.
- •Individuals with a Fasting Blood glucose (FBG) ≤ 125 mg/dl
- •All individuals who are free from use of sleeping pills for at least 4 weeks before screening
- •Individuals with normal levels of laboratory parameters: Liver profile, Lipid profile and kidney profile. [Refer to section 3.7.3 for details on parameters included and reference ranges.]
- •Individuals with no more than once per week use of pain-relieving medications.
- •Individuals with body mass index between ≥18 and ≤ 30 kg/m
- •Typical bedtime between 9 PM and 11 PM.
- •Individuals willing to abstain from digital activity 3 hours prior to the PSG analysis
- •Willing to maintain current dietary pattern, activity level, and stable body weight for the duration of the study, and refrain from any drastic lifestyle changes.
排除标准
- •FBG > 125 mg/dl
- •Individuals diagnosed with hypertension.
- •Individuals having a systolic blood pressure ≥140 mm Hg and diastolic blood pressure ≥ 90 mm Hg.
- •Individuals diagnosed with Type I and Type II Diabetes Mellitus.
- •Sleep disorder is secondary to another health problem such as restless leg syndrome, post-operative state etc.
- •Individuals diagnosed with insomnia.
- •Consumption of hypnotic drugs (<3 months before inclusion)
- •Individuals taking any other sleep promoting supplements and are unwilling to stop taking those supplements for the duration of the study period
- •Individuals with history of sleepwalk
- •Individuals who have bad dreams 2 or more times a week.
- •Individuals who are inclined to the lifestyle factors - such as jet lag, night workers and rotational shift work.
- •Individuals who currently, or in the past 6 months suffered from any mental-health disorder
- •Individuals who were taking psychotropic medication, herbal preparation, antidepressants, steroids, antihistamines, narcotics or any other illicit drugs in the last three months.
- •Individuals diagnosed with chronic medical conditions - such as heart problems, Gastro-intestinal, hepatic, respiratory, psychiatric, kidney, or cardiovascular disorder (<3 months before inclusion), and chronic pain since last 6 months.
- •Recent (within 3 months before inclusion) change in lifestyle (food, sport and drug).
- •Individuals who are regular smokers and/or consume any form of tobacco.
- •Addiction, history of addiction, and/or substance abuse (tobacco, nicotine etc.).
- •Heavy drinkers as defined by:
- •For men, consuming more than 4 drinks on any day or more than 14 drinks/week
- •For women, consuming more than 3 drinks on any day or more than 7 drinks/week
- •Exaggerated consumption of tea (≥500 mL per day), coffee (≥400 mL per day), or energy drink (≥250 mL per day),
- •Individuals on dietary supplements
- •Pregnant or lactating woman,
- •Lifestyle habits which would modify the wake-sleep rhythm or which was expected to be modified during the study period (e.g., night work)
- •Known allergy to mushroom.
结局指标
主要结局
To assess the efficacy of Vl-NL-02 on sleep quality using the Insomnia Severity Index (ISI).
时间窗: Day 22 of intervention
The Insomnia Severity Index has seven questions that indicates insomnia without clinical significance. The scores of 0-7 determines no clinically significant insomnia, 8-14 determines sub threshold insomnia, 15-21 has moderate severity which determines clinical insomnia and lastly 22-28 has severe insomnia. For each question, participant will be asked to circle or mark the number that best correlates with their sleep quality in the past two weeks. An increase in score will determine the severity of the insomnia.
次要结局
- To assess impact of VL-NL-02 on Mood using Brief Mood Introspection Scale (BMIS)(Day 1, 11 and 22 of intervention)
- To assess impact of VL-NL-02 on Improvement in deep sleep and Rapid eye movement (REM) sleep stages by Polysomnography(Day 0, 10 and 21 of intervention)
- To assess impact of VL-NL-02 on Levels of salivary cortisol immediately after awakening(Day 1 and 22 of Intervention)
- To assess impact of VL-NL-02 on Dream as assessed by Dream and Sleep Emotions and Anxiety (DSEA) Questionnaire(Day 1, 11 and 22 of intervention)
- To assess impact of VL-NL-02 on Levels of urinary melatonin(Day 1 and 22 of Intervention)
- To assess impact of VL-NL-02 on Restorative sleep by using Restorative Sleep Questionnaire - Weekly Version (RSQ-W) questionnaire(Day 1, 11 and 22 of intervention)
- To assess impact of VL-NL-02 on Quality of life using RAND Short form (SF)-36(Day 1, 11 and 22 of intervention)
- To assess impact of VL-NL-02 on Levels of serum Brain Derived Neurotrophic Factor (BDNF)(Day 1 and 22 of Intervention)
- To assess impact of VL-NL-02 on Levels of serum serotonin(Day 1 and 22 of Intervention)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
2 期
Trial Evaluating Paliperidone Extended-Release (ER) Tablets Versus Placebo on Sleep in Schizophrenia PatientsSchizophreniaInsomniaNCT00105326Johnson & Johnson Pharmaceutical Research & Development, L.L.C.5
终止
3 期
Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)Primary InsomniaNCT00420810H. Lundbeck A/S138
已完成
1 期
A Study of LY2624803 in Participants With Transient InsomniaTransient InsomniaNCT01779830Eli Lilly and Company32
已完成
不适用
Evidence-based information and communications technology tools for weight loss maintenanceOverweight and obese adults who have achieved clinically significant weight loss (5%)ObesityISRCTN88405328The University of Leeds1,600
已完成
不适用
Evaluation of a Food Supplement on Sleep QualityInsomniaNCT00484497Persee Medica105